Xylem Inc. filed its Form 10-Q with the SEC on October 27, 2026, covering the quarterly period ended September 30, 2026, reporting third-quarter and year-to-date financial results for the water technology company listed on NYSE:XYL.

Key Highlights

  • Nine-month revenue: Xylem reported total revenue of $6,662 million for the nine months ended September 30, 2026, compared with $6,638 million in the same period of 2025, according to the filing.
  • Third-quarter net income attributable to Xylem: $291 million for the three months ended September 30, 2026, up from $227 million in the prior-year quarter.
  • Nine-month net income attributable to Xylem: $747 million for the nine months ended September 30, 2026, compared with $622 million in the same 2025 period.
  • Diluted earnings per share: $1.25 for the third quarter and $3.14 for the first nine months of 2026, the filing disclosed.
  • Long-term debt: Long-term debt, net rose to $2,365 million as of September 30, 2026, from $1,408 million as of December 31, 2025.
  • Cash and cash equivalents: Declined to $708 million as of September 30, 2026, from $1,479 million as of December 31, 2025, according to the balance sheet.
  • Outstanding shares: As of October 23, 2026, there were 229,334,592 shares of common stock outstanding, the filing stated.

Xylem's Third-Quarter and Year-to-Date Financial Position Through September 2026

Xylem Inc., a water technology company headquartered at 301 Water Street SE, Washington, DC, reported third-quarter 2026 revenue of $2,201 million, down from $2,268 million in the third quarter of 2025, according to the condensed consolidated income statements included in the filing. Revenue from products was $1,807 million and revenue from services was $394 million for the three-month period, the company disclosed. Gross profit for the quarter was $907 million, compared with $883 million in the year-ago quarter.

For the nine months ended September 30, 2026, Xylem reported operating income of $1,019 million, up from $870 million in the same period of 2025. Restructuring and asset impairment charges totaled $50 million for the nine-month period, compared with $70 million in the prior-year period, according to the filing. Interest expense rose to $32 million for the nine months ended September 30, 2026, from $23 million in the comparable 2025 period, and the company recorded a loss on sale of businesses of $17 million, the filing stated.

On the balance sheet, total assets stood at $17,326 million as of September 30, 2026, compared with $17,634 million as of December 31, 2025. Goodwill was reported at $8,524 million as of September 30, 2026. The filing also disclosed that treasury stock stood at 30.0 million shares as of September 30, 2026, compared with 16.3 million shares as of December 31, 2025. Net cash provided by operating activities for the nine months ended September 30, 2026, was $729 million, while capital expenditures were $268 million and acquisitions of businesses, net of cash acquired, totaled $425 million, according to the cash flow statement.

What Was Disclosed

Xylem's Form 10-Q for the period ended September 30, 2026, disclosed nine-month revenue of $6,662 million, net income attributable to Xylem of $747 million, diluted EPS of $3.14, and a balance sheet showing total assets of $17,326 million and long-term debt of $2,365 million.